Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization

Oncogene volume 18, pages 1619–1627 (1999)Cite this article

Abstract

We have previously reported the identification of four autophosphorylation sites on the KDR VEGF receptor. Two of these sites (tyrosines 951 and 996) are located in the receptor's kinase insert domain, and two (tyrosines 1054 and 1059) are located in the catalytic domain. In order to clarify the functional significance of these sites, we made DNA constructs in which tyrosine codons were replaced with those for phenylalanine, and expressed the DNA constructs in 293 cells. VEGF binding to cells expressing the native receptor led to a rapid increase in receptor and PLCγ phosphorylation, and a slower increase in the phosphorylation of p125FAK and paxillin. VEGF binding to KDR(Y951F) and KDR(Y996F) expressing cells resulted in phosphorylation of all cellular substrates tested, although the level of PLCγ phosphorylation was decreased for KDR(Y996F). The decreased level of PLCγ phosphorylation was not because PLCγ-containing SH2 domains bind to the Y996 autophosphorylation site. We conclude that there exists receptor autophosphorylation sites not previously identified which allow for signaling via PLCγ, as well as p125FAK and paxillin. VEGF binding to cells expressing KDR mutated at both tyrosine's 1054 and 1059 activated receptor autophosphorylation but at a level which was only 10% of that seen for cells expressing native receptor. Tyrosine phosphorylation of cell signaling proteins was not observed in KDR(Y1054,1059) expressing cells. Utilizing an in vitro assay which directly measures receptor catalytic activity allowed us to determine that the tyrosine kinase activity of the native receptor was significantly greater than that for the double mutant. We conclude from this result that VEGF-induced autophosphorylation at tyrosines 1054 and 1059 is a required step for allowing maximal KDR kinase activity. Maximal rates of receptor kinase activity is required for VEGF-induced receptor internalization, as internalization was delayed in the KDR(Y1054,1059F) expressing cells when compared to cells expressing native receptor.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  • Abedi H and Zachary I. . 1997 J. Biol. Chem. 272: 15442–15451.

  • Aiello LP, Avery R, Arrigg R, Key B, Jampel H, Shah S, Pasquale L, Thieme H, Iwamoto M, Park JE, Nguye H, Aiello LM, Ferrara N and King GL. . 1994 N. Engl. J. Med. 331: 1480–1487.

  • Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR and Dvorak HF. . 1993 Am. J. Pathol. 143: 1255–1262.

  • Broxmeyer HE, Cooper S, Li ZH, Song HY, Kwon BS, Warren RS and Donner DB. . 1995 Int. J. Hematol. 62: 203–215.

  • Cullinan-Bove K and Koos RD. . 1993 Endocrinology 133: 829–837.

  • Cunningham SA, Arrate MP, Brock TA and Waxham MN. . 1997 Biochem. Biophys. Res. Com. 240: 35–39.

  • De Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N and Williams LT. . 1992 Science 255: 989–991.

  • Dougher-Vermazen M, Hulmes JD, Bohlen P and Terman BI. . 1994 Biochem. Biophys. Res. Commun. 205: 728–738.

  • Dougher M, Wasserstrom HA, Torley L, Shridaran L, Wesdock P, Hileman RE, Fromm JR, Anderberg R, Lyman S, Linhardt RJ, Kaplan J and Terman BT. . 1997 Growth Factors 14: 257–268.

  • Dvorak HF, Brown LF, Detmar M and Dvorak AM. . 1995 Am. J. Pathol. 146: 1029–1039.

  • Ellis L, Clauser E, Morgan DO, Edery E, Roth RA and Ruttler WJ. . 1986 Cell 45: 721–732.

  • Fantl WJ, Escobedo JA, Martin GA, Turck CW, del Rosario M, McCormick F and Williams LT. . 1992 Cell 69: 413–423.

  • Fava RA, Olsen NJ, Spencer-Green G, Yeo T-K, Yeo K-T, Berse B, Jackman RW, Senger DR, Dvorak HF and Brown LF. . 1994 J. Exp. Med. 180: 340–346.

  • Ferrara N and Davis-Smith T. . 1997 Endocrine Reviews 18: 4–25.

  • Folkman J. . 1991 J. Natl. Cancer Inst. 82: 4–6.

  • Folkman J and Shing Y. . 1992 J. Biol. Chem. 267: 10931–10934.

  • Fong G-H, Rossant J, Gertsenstein M and Breitman ML. . 1995 Nature 376: 66–70.

  • Garner A. . 1994 Pathobiology of Ocular Disease. In: A Dynamic Approach, Garner A, Klintworth GK (eds)., 2nd edn.. Marcel Dedder: New York pp. 1625–1710.

    Google Scholar 

  • Gospodarowicz D, Abraham JA and Schilling J. . 1989 Proc. Natl. Acad. Sci. USA. 86: 7311–7315.

  • Guo D, Jia W, Song H-Y, Warren RS and Donner DB. . 1995 J. Biol. Chem. 270: 6729–6733.

  • Hubbard SR, Weil A, Ellis L and Hendrickson WA. . 1994 Nature 372: 746–754.

  • Hubbard SR, Mohammadi M and Schlessinger J. . 1998 J. Biol. Chem. 273: 11987–11990.

  • Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N. . 1993 Nature 36: 841–844.

  • Leung DW, Cachianes G, Kuang W-J, Goeddel DV and Ferrara N. . 1989 Science 246: 1306–1309.

  • Longati P, Bardelli A, Ponzetto C, Naldini L and Comoglio PM. . 1994 Oncogene 9: 3457–3465.

  • Margolis B, Lax I, Kris R, Dombalagian M, Honegger AM, Howk R, Givol D, Ullrich A and Schlessinger J. . 1989 J. Biol. Chem. 264: 10667–10671.

  • Matthews W, Jordan CT, Gavin M, Jenkins NA, Copeland NG and Lemischka IR. . 1991 Proc. Natl. Acad. Sci. USA 88: 9026–9030.

  • Millauer B, Shawver LK, Plate KH, Risau W and Ullrich A. . 1994 Nature 367: 576–579.

  • Mohammadi M, Honegger AM, Rotin D, Fischer R, Bellot F, Li W, Dionne A, Jaye M, Rubinstein M and Schlessinger J. . 1991 Mol. Cellular. Biol. 11: 5068–5078.

  • Mohammadi M, Dikic I, Sorokin A, Burgess WH, Jaye M and Schlessinger J. . 1996 Molecular and Cellular Biology 16: 977–989.

  • Pepper MS, Ferrara N, Orci L and Montesano R. . 1991 Biochem. Biophys. Res. Commun. 181: 902–908.

  • Prudovsky I, Savion N, Zhau X, Friesal R, Xu J, Xou J, Mckeehan WL and Maciag T. . 1994 J. Biol. Chem. 269: 31720–31724.

  • Scatchard G. . 1949 Ann. NY. Acad. Sci. 51: 660–672.

  • Seetheram L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S and Shibuya M. . 1995 Oncogene 10: 135–147.

  • Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF. . 1983 Science 219: 983–985.

  • Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu X-F, Britman ML and Schuh AC. . 1995 Nature 376: 62–66.

  • Shibuya M, Yamguchi S, Yamane A, Ikeda T, Tojo A, Hitoshi M and Sato M. . 1990 Oncogene 5: 519–523.

  • Takahashi T and Shibuya M. . 1997 Oncogene 14: 2079–2089.

  • Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armelino DC, Gospodarowicz D and Bohlen P. . 1992 Biochem. Biophys. Res. Commun. 187: 1579–1586.

  • Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N and Adamis AP. . 1996 Arch. Ophthalmol. 114: 964–970.

  • Ullrich A and Schlessinger J. . 1990 Cell 61: 203–212.

  • Vaisman N, Gospodarowicz D and Neufeld G. . 1990 J. Biol. Chem. 265: 19461–19469.

  • Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M and Heldin C-H. . 1994 J. Biol. Chem. 269: 26988–26995.

  • Wilden PA, Siddle K, Haring E, Backer JM, White MF and Kahn CR. . 1992 J. Biol. Chem. 267: 13719–13727.

  • Wiley HS, Herbst JJ, Walsh BJ, Laufferburger DA, Rosenfeld MG and Gill GN. . 1991 J. Biol. Chem. 266: 11083–11094.

Download references

Author information

Authors and Affiliations

  1. Wyeth-Ayerst Oncology Research, Building 200/4623, Pearl River, New York, 10965, USA

    Maureen Dougher & Bruce I Terman

Authors
  1. Maureen Dougher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruce I Terman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dougher, M., Terman, B. Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene 18, 1619–1627 (1999). https://doi.org/10.1038/sj.onc.1202478

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1202478

Keywords

This article is cited by

Search

Advanced search

Quick links